Compounds > lk 423
Page last updated: 2024-12-11

lk 423

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-(2-(2-phthalimidoethoxy)acetyl)-L-alanyl-D-glutamic acid: RN & structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5491958
SCHEMBL ID3053903
MeSH IDM0302121

Synonyms (10)

Synonym
n-(2-(2-phthalimidoethoxy)acetyl)-l-alanyl-d-glutamic acid
(2r)-2-[[(2s)-2-[[2-[2-(1,3-dioxoisoindol-2-yl)ethoxy]acetyl]amino]propanoyl]amino]pentanedioic acid
142489-47-2
lk423
lk 423
lk-423
SCHEMBL3053903
DTXSID80162059
(r)-2-((s)-2-(2-(2-(1,3-dioxoisoindolin-2-yl)ethoxy)acetamido)propanamido)pentanedioic acid
(2r)-2-[(2s)-2-{2-[2-(1,3-dioxo-2,3-dihydro-1h-isoindol-2-yl)ethoxy]acetamido}propanamido]pentanedioic acid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" As optimized delivery to the site of action appears crucial for further preclinical development of LK-423, the aim of this study was to perform a physicochemical and preclinical pharmacokinetic and toxicological evaluation."( Physicochemical and preclinical pharmacokinetic and toxicological evaluation of LK-423--a new phthalimido-desmuramyl-dipeptide derivative with immunomodulating activity.
Andrensek, S; Bogataj, M; Cerne, M; Grabnar, I; Kovacic, N; Kristl, A; Locatelli, I; Mrhar, A; Smrdel, P; Urleb, U, 2009)		0.35
" A pharmacokinetic study following intravenous application to rats and dogs revealed that LK-423 is rapidly eliminated with a short terminal phase half-life, and high plasma clearance, as well as a limited distribution to the peripheral tissue."( Physicochemical and preclinical pharmacokinetic and toxicological evaluation of LK-423--a new phthalimido-desmuramyl-dipeptide derivative with immunomodulating activity.
Andrensek, S; Bogataj, M; Cerne, M; Grabnar, I; Kovacic, N; Kristl, A; Locatelli, I; Mrhar, A; Smrdel, P; Urleb, U, 2009)		0.35

Bioavailability

ExcerptReferenceRelevance
" Oral bioavailability of LK-423 is low, presumably due to low permeability."( Physicochemical and preclinical pharmacokinetic and toxicological evaluation of LK-423--a new phthalimido-desmuramyl-dipeptide derivative with immunomodulating activity.
Andrensek, S; Bogataj, M; Cerne, M; Grabnar, I; Kovacic, N; Kristl, A; Locatelli, I; Mrhar, A; Smrdel, P; Urleb, U, 2009)		0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (40.00)18.2507
2000's2 (40.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.66

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.66 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.45 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.66)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
theophylline
[no description available]		2.0410dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent
n-vinyl-2-pyrrolidinone
N-vinyl-2-pyrrolidinone: monomer of POVIDONE; structure given in first source		2.0410pyrrolidin-2-ones
trinitrobenzenesulfonic acid
Trinitrobenzenesulfonic Acid: A reagent that is used to neutralize peptide terminal amino groups.. 2,4,6-trinitrobenzenesulfonic acid : The arenesulfonic acid that is benzenesulfonic acid with three nitro substituents in the 2-, 4- and 6-positions.		2.0510arenesulfonic acid;
C-nitro compound		epitope;
explosive;
reagent
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0510
Colitis
Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.		07.4220
Colitis Gravis
[description not available]		0210
Colitis, Ulcerative
Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.		0210